High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in...

Full description

Bibliographic Details
Main Authors: Ann W. Silk, Howard L. Kaufman, Brendan Curti, Janice M. Mehnert, Kim Margolin, David McDermott, Joseph Clark, Jenna Newman, Praveen K. Bommareddy, Lisa Denzin, Saltanat Najmi, Azra Haider, Weichung Shih, Michael P. Kane, Andrew Zloza
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Oncology
Subjects:
melanoma
interleukin-2
cytokine
ipilimumab
combination immunotherapy
hepatitis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01483/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01483/full

Similar Items